Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis

Charles Y C Pak, Roy D. Peterson, John Poindexter

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Purpose: We determine if potassium citrate treatment stabilizes spinal bone density among patients with recurrent calcium oxalate nephrolithiasis. Materials and Methods: We studied a group of 16 men and 5 women with stones taking potassium citrate from 11 to 120 months. They represented all patients from the Stone Clinic who took potassium citrate alone for at least 11 months. L2-L4 bone mineral density data before and after potassium citrate treatment were retrieved retrospectively and analyzed. Results: In the combined group L2-L4 bone mineral density increased significantly by 3.1% over mean duration of 44 months. Z score, corrected for age matched normal values, increased significantly by 3.8%. Urinary pH, citrate and potassium increased significantly during treatment but urinary calcium did not change. Conclusions: Potassium citrate, a commonly used drug for the prevention of recurrent nephrolithiasis, may avert age dependent bone loss. Spinal bone density increased in most patients when it normally decreases.

Original languageEnglish (US)
Pages (from-to)31-34
Number of pages4
JournalJournal of Urology
Volume168
Issue number1
StatePublished - 2002

Fingerprint

Potassium Citrate
Urolithiasis
Calcium
Bone and Bones
Bone Density
Nephrolithiasis
Reference Values
Therapeutics
Pharmaceutical Preparations

Keywords

  • Bone density
  • Calculi
  • Potassium citrate

ASJC Scopus subject areas

  • Urology

Cite this

Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis. / Pak, Charles Y C; Peterson, Roy D.; Poindexter, John.

In: Journal of Urology, Vol. 168, No. 1, 2002, p. 31-34.

Research output: Contribution to journalArticle

Pak, Charles Y C ; Peterson, Roy D. ; Poindexter, John. / Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis. In: Journal of Urology. 2002 ; Vol. 168, No. 1. pp. 31-34.
@article{6e21ffca7204414d8973ab1e2bf6211d,
title = "Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis",
abstract = "Purpose: We determine if potassium citrate treatment stabilizes spinal bone density among patients with recurrent calcium oxalate nephrolithiasis. Materials and Methods: We studied a group of 16 men and 5 women with stones taking potassium citrate from 11 to 120 months. They represented all patients from the Stone Clinic who took potassium citrate alone for at least 11 months. L2-L4 bone mineral density data before and after potassium citrate treatment were retrieved retrospectively and analyzed. Results: In the combined group L2-L4 bone mineral density increased significantly by 3.1{\%} over mean duration of 44 months. Z score, corrected for age matched normal values, increased significantly by 3.8{\%}. Urinary pH, citrate and potassium increased significantly during treatment but urinary calcium did not change. Conclusions: Potassium citrate, a commonly used drug for the prevention of recurrent nephrolithiasis, may avert age dependent bone loss. Spinal bone density increased in most patients when it normally decreases.",
keywords = "Bone density, Calculi, Potassium citrate",
author = "Pak, {Charles Y C} and Peterson, {Roy D.} and John Poindexter",
year = "2002",
language = "English (US)",
volume = "168",
pages = "31--34",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Prevention of spinal bone loss by potassium citrate in cases of calcium urolithiasis

AU - Pak, Charles Y C

AU - Peterson, Roy D.

AU - Poindexter, John

PY - 2002

Y1 - 2002

N2 - Purpose: We determine if potassium citrate treatment stabilizes spinal bone density among patients with recurrent calcium oxalate nephrolithiasis. Materials and Methods: We studied a group of 16 men and 5 women with stones taking potassium citrate from 11 to 120 months. They represented all patients from the Stone Clinic who took potassium citrate alone for at least 11 months. L2-L4 bone mineral density data before and after potassium citrate treatment were retrieved retrospectively and analyzed. Results: In the combined group L2-L4 bone mineral density increased significantly by 3.1% over mean duration of 44 months. Z score, corrected for age matched normal values, increased significantly by 3.8%. Urinary pH, citrate and potassium increased significantly during treatment but urinary calcium did not change. Conclusions: Potassium citrate, a commonly used drug for the prevention of recurrent nephrolithiasis, may avert age dependent bone loss. Spinal bone density increased in most patients when it normally decreases.

AB - Purpose: We determine if potassium citrate treatment stabilizes spinal bone density among patients with recurrent calcium oxalate nephrolithiasis. Materials and Methods: We studied a group of 16 men and 5 women with stones taking potassium citrate from 11 to 120 months. They represented all patients from the Stone Clinic who took potassium citrate alone for at least 11 months. L2-L4 bone mineral density data before and after potassium citrate treatment were retrieved retrospectively and analyzed. Results: In the combined group L2-L4 bone mineral density increased significantly by 3.1% over mean duration of 44 months. Z score, corrected for age matched normal values, increased significantly by 3.8%. Urinary pH, citrate and potassium increased significantly during treatment but urinary calcium did not change. Conclusions: Potassium citrate, a commonly used drug for the prevention of recurrent nephrolithiasis, may avert age dependent bone loss. Spinal bone density increased in most patients when it normally decreases.

KW - Bone density

KW - Calculi

KW - Potassium citrate

UR - http://www.scopus.com/inward/record.url?scp=0036279215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036279215&partnerID=8YFLogxK

M3 - Article

VL - 168

SP - 31

EP - 34

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -